The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
A substantial level of evidence supports the use of renin system blockade for many patients with hypertension. Two lines of evidence, based on very high-dose angiotensin blocker treatment or combination therapy with angiotensin-converting enzyme inhibitor and angiotensin receptor blocker, suggest that more complete blockade leads to improved clinical outcomes. The recent development of a powerful renin inhibitor that acts at the initial, rate-limiting step in the renin cascade would also favor more complete blockade of the system. For many patients, this is likely to lead to improved treatment.
Hollenberg
Norman K
NK
Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome; D000092502:Renin Inhibitors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D012083:Renin; D000092502:Renin Inhibitors